Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents☆

Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide

Merrifield, R. B. (1963) · Journal of the American Chemical Society · doi:10.1021/ja00897a025 · Cited by 7,645 · see citing works

A highly sensitive adenylate cyclase assay

Salomon, Y., Londos, C., & Rodbell, M. (1974) · Analytical Biochemistry · doi:10.1016/0003-2697(74)90222-x · Cited by 4,188 · see citing works

Oxytocin increases trust in humans

Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., & Fehr, E. (2005) · Nature · doi:10.1038/nature03701 · Cited by 3,690 · see citing works

The oxytocin receptor system: structure, function, and regulation

Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089 · see citing works

Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans

Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639 · see citing works

Tolvaptan, a Selective Oral Vasopressin V ₂ -Receptor Antagonist, for Hyponatremia

Schrier, R. W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J. G., Czerwiec, F. S., & Orlandi, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065181 · Cited by 1,215 · see citing works

The neurobiology of attachment

Insel, T. R., & Young, L. J. (2001) · Nature Reviews Neuroscience · doi:10.1038/35053579 · Cited by 1,173 · see citing works

Solid Phase Synthesis

Merrifield, B. (1986) · Science · doi:10.1126/science.3961484 · Cited by 1,005 · see citing works

More than one reason to rethink the use of peptides in vaccine design

Purcell, A. W., McCluskey, J., & Rossjohn, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2224 · Cited by 853 · see citing works

Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure<SUBTITLE>The EVEREST Clinical Status Trials</SUBTITLE>

Gheorghiade, M. (2007) · JAMA · doi:10.1001/jama.297.12.1332 · Cited by 841 · see citing works

Vasopressin and Oxytocin Excite Distinct Neuronal Populations in the Central Amygdala

Huber, D., Veinante, P., & Stoop, R. (2005) · Science · doi:10.1126/science.1105636 · Cited by 804 · see citing works

Oxytocin Increases Retention of Social Cognition in Autism

Hollander, E., Bartz, J., Chaplin, W., Phillips, A., Sumner, J., Soorya, L., Anagnostou, E., & Wasserman, S. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.030 · Cited by 693 · see citing works

Oxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders

Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C. M., Aronowitz, B. R., & Mosovich, S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300021 · Cited by 689 · see citing works

Structure and expression of a human oxytocin receptor

Kimura, T., Tanizawa, O., Mori, K., Brownstein, M., & Okayama, H. (1992) · Nature · doi:10.1038/356526a0 · Cited by 631 · see citing works

Molecular cloning of the receptor for human antidiuretic hormone

Birnbaumer, M., Seibold, A. M., Gilbert, S., Ishido, M., Barberis, C., Antaramián, A., Brabet, P., & Rosenthal, W. (1992) · Nature · doi:10.1038/357333a0 · Cited by 539 · see citing works

Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus

Lolait, S. J., O'Carroll, A.-M., McBride, O. W., Konig, M., Morel, A., & Brownstein, M. J. (1992) · Nature · doi:10.1038/357336a0 · Cited by 524 · see citing works

Prevention and Treatment of Major Blood Loss

Mannucci, P. M., & Levi, M. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmra067742 · Cited by 492 · see citing works

Molecular cloning and expression of a rat Via arginine vasopressin receptor

Morel, A., O'Carroll, A.-M., Brownstein, M. J., & Lolaft, S. J. (1992) · Nature · doi:10.1038/356523a0 · Cited by 477 · see citing works

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V _1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders

Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471 · see citing works

[1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine]arginine-vasopressin and [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)]arginine-vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressin

Kruszynski, M., Lammek, B., Manning, M., Seto, J., Haldar, J., & Sawyer, W. H. (1980) · Journal of Medicinal Chemistry · doi:10.1021/jm00178a003 · Cited by 450 · see citing works

Brain Oxytocin Correlates with Maternal Aggression: link to Anxiety

Bosch, O. J., Meddle, S. L., Beiderbeck, D. I., Douglas, A. J., & Neumann, I. D. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1342-05.2005 · Cited by 439 · see citing works

The Synthesis of Oxytocin1

du Vigneaud, V., Ressler, C., SWAN, J. M., Roberts, C. W., & Katsoyannis, P. G. (1954) · Journal of the American Chemical Society · doi:10.1021/ja01641a004 · Cited by 422 · see citing works

Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor.

Sugimoto, T., Saito, M., Mochizuki, S., Watanabe, Y., Hashimoto, S., & Kawashima, H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47129-3 · Cited by 376 · see citing works

Science review: Vasopressin and the cardiovascular system part 1--receptor physiology.

(2003) · Critical Care · doi:10.1186/cc2337 · Cited by 356 · see citing works

Characterization of a novel aquaretic agent, OPC‐31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist

Yamamura, Y., Ogawa, H., Yamashita, H., Chihara, T., Miyamoto, H., Nakamura, S., Onogawa, T., Yamashita, T., Hosokawa, T., Mori, T., et al. (1992) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1992.tb09058.x · Cited by 346 · see citing works

OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological Profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats

Yamamura, Y., Nakamura, S., Itoh, S., Hirano, T., Onogawa, T., Yamashita, T., Yamada, Y., Tsujimae, K., Aoyama, M., Kotosai, K., et al. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37873-5 · Cited by 338 · see citing works

Oxytocin and Vasopressin V1a and V2 Receptors Form Constitutive Homo- and Heterodimers during Biosynthesis

Terrillon, S., Durroux, T., Mouillac, B., Breit, A., Ayoub, M. A., Taulan‐Cadars, M., Jockers, R., Barberis, C., & Bouvier, M. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0222 · Cited by 323 · see citing works

Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications

Ring, R. H., Malberg, J. E., Potestio, L., Ping, J., Boikess, S., Luo, B., Schechter, L. E., Rizzo, S., Rahman, Z., & Rosenzweig-Lipson, S. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0293-z · Cited by 319 · see citing works

The Vasopressin System

Treschan, T. A., Peters, J., & Warltier, D. C. (2006) · Anesthesiology · doi:10.1097/00000542-200609000-00026 · Cited by 317 · see citing works

An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: A randomized, double-blind, placebo-controlled trial with tocolytic rescue

Romero, R. J., Sibai, B. M., Sanchez‐Ramos, L., Valenzuela, G. J., Veille, J., Tabor, B. L., Perry, K. G., Varner, M. W., Goodwin, T. M., Lane, R., et al. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2000.95834 · Cited by 316 · see citing works

EFFECT OF MAGNESIUM ION ON THE RESPONSE OF THE RAT UTERUS TO NEUROHYPOPHYSIAL HORMONES AND ANALOGUES1

Munsick, R. A. (1960) · Endocrinology · doi:10.1210/endo-66-3-451 · Cited by 302 · see citing works

Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series

Daniels, D. J., Lenard, N. R., Etienne, C. L., Law, P., Roerig, S. C., & Portoghese, P. S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506627102 · Cited by 297 · see citing works

Oxytocin, vasopressin and pair bonding: implications for autism

Hammock, E. A. D., & Young, L. J. (2006) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2006.1939 · Cited by 289 · see citing works

Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor.

Thibonnier, M., Auzan, C., Madhun, Z. T., Wilkins, P. L., Berti‐Mattera, L. N., & Clauser, É. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41863-1 · Cited by 281 · see citing works

Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis.

Jard, S., Gaillard, R. C., Guillon, G., Marie, J., Schoenenberg, P., Muller, A. F., Manning, M., & Sawyer, W. H. (1986) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10336-2 · Cited by 276 · see citing works

Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

Gal, C. S., Wagnon, J., Garcia, C., Lacour, C., Guiraudou, P., Christophe, B., Villanova, G., Nisato, D., Maffrand, J., & Fur, G. L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116554 · Cited by 272 · see citing works

OPC-21268, an Orally Effective, Nonpeptide Vasopressin V1 Receptor Antagonist

Yamamura, Y., Ogawa, H., Chihara, T., Kondo, K., Onogawa, T., Nakamura, S., Mori, T., Tominaga, M., & Yabuuchi, Y. (1991) · Science · doi:10.1126/science.1850553 · Cited by 271 · see citing works

Centrally released oxytocin mediates mating-induced anxiolysis in male rats

Waldherr, M., & Neumann, I. D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705860104 · Cited by 261 · see citing works

THE QUANTITATIVE ASSAY OF VASOPRESSIN

Dekanski, J. (1952) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1952.tb00723.x · Cited by 259 · see citing works

Social facilitation of wound healing

Detillion, C. E., Craft, T. K. S., Glasper, E. R., Prendergast, B. J., & DeVries, A. C. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2003.10.003 · Cited by 259 · see citing works

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

Gal, C. S., Lacour, C., Valette, G., Garcia, G., Foulon, L., Galindo, G., Bankir, L., Pouzet, B., Guillon, G., Barberis, C., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119098 · Cited by 249 · see citing works

125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH29]OVT: a selective oxytocin receptor ligand

Elands, J., Barberis, C., Jard, S., Tribollet, E., Dreifuss, J.-J., Bankowski, K., Manning, M., & Sawyer, W. H. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90778-9 · Cited by 245 · see citing works

Pharmacologic Chaperones as a Potential Treatment for X-Linked Nephrogenic Diabetes Insipidus

Bernier, V., Morello, J.-P., ZARRUK, A. R., Debrand, N., Salahpour, A., Lonergan, M., Arthus, M., Laperrière, A., Brouard, R., Bouvier, M., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005080854 · Cited by 244 · see citing works

A MODIFICATION OF THE METHOD OF DALE AND LAIDLAW FOR STANDARDIZATION OF POSTERIOR PITUITARY EXTRACT

Holton, P. (1948) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1948.tb00396.x · Cited by 242 · see citing works

Rapid accumulation of inositol phosphates in isolated rat superior cervical sympathetic ganglia exposed to V1-vasopressin and muscarinic cholinergic stimuli

Bone, E. A., Fretten, P., Palmer, S., Kirk, C. J., & Michell, R. H. (1984) · Biochemical Journal · doi:10.1042/bj2210803 · Cited by 221 · see citing works

Recent Advances in Protein and Peptide Drug Delivery Systems

Malik, D. K., Baboota, S., Ahuja, A., Hasan, S., & Ali, J. (2007) · Current Drug Delivery · doi:10.2174/156720107780362339 · Cited by 216 · see citing works

Characterization of (2 S,4 R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist

Gal, C. S.-L., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., Barberis, C., Brossard, G., Soubrié, P., Nisato, D., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1122 · Cited by 211 · see citing works

Sensitivity to Intranasal Oxytocin in Adult Men with Early Parental Separation

Meinlschmidt, G., & Heim, C. C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.007 · Cited by 210 · see citing works

Cloning and characterization of the human V3 pituitary vasopressin receptor

de Keyzer, Y., Auzan, C., Lenne, F., Beldjord, C., Thibonnier, M., Bertagna, X., & Clauser, E. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)01268-7 · Cited by 209 · see citing works

Intranasal oxytocin administration attenuates the ACTH stress response in monkeys

Parker, K. J., Buckmaster, C. L., Schatzberg, A. F., & Lyons, D. M. (2005) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.04.002 · Cited by 204 · see citing works

Release of Oxytocin in the Rat Central Amygdala Modulates Stress-Coping Behavior and the Release of Excitatory Amino Acids

Ebner, K., Bosch, O. J., Krömer, S. A., Singewald, N., & Neumann, I. D. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300607 · Cited by 200 · see citing works

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology.

Holmes, C. L., Landry, D. W., & Granton, J. T. (2003) · Critical Care · doi:10.1186/cc2338 · Cited by 195 · see citing works

Efficacy and Safety of Oral Conivaptan: A V1A/V2Vasopressin Receptor Antagonist, Assessed in a Randomized, Placebo-Controlled Trial in Patients with Euvolemic or Hypervolemic Hyponatremia

Ghali, J. K., Koren, M. J., Taylor, J. R., Brooks-Asplund, E. M., Fan, K., Long, W. A., & Smith, N. N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2287 · Cited by 193 · see citing works

A SYNTHETIC PREPARATION POSSESSING BIOLOGICAL PROPERTIES ASSOCIATED WITH ARGININEVASOPRESSIN

du Vigneaud, V., Gish, D. T., & Katsoyannis, P. G. (1954) · Journal of the American Chemical Society · doi:10.1021/ja01647a089 · Cited by 192 · see citing works

(3H)-Vasopressin Binding to Isolated Rat Hepatocytes and Liver Membranes: Regulation by GTP and Relation to Glycogen Phosphorylase Activation

Cantau, B., Keppens, S., WULF, H. D., & Jard, S. (1980) · Journal of Receptor Research · doi:10.3109/10799898009044096 · Cited by 164 · see citing works

Novel Ligand Specificity of Pituitary Vasopressin Receptors in the Rat

Antoni, F. A. (2008) · Neuroendocrinology · doi:10.1159/000123976 · Cited by 159 · see citing works

Discovery, development, and some uses of vasopressin and oxytocin antagonists.

Manning, M., & Sawyer, W. H. (1989) · PubMed · Cited by 151 · see citing works

5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]- [1,4]benzodiazepin-10(11H)-ylcarbonyl)-3- chlorophenyl]benzamide (VPA-985): An Orally Active Arginine Vasopressin Antagonist with Selectivity for V2Receptors

Albright, J. D., Reich, M. F., Santos, E. G. D., Dusza, J. P., Sum, F., Venkatesan, A. M., Coupet, J., Chan, P. S., Ru, X., Mazandarani, H., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980179c · Cited by 151 · see citing works

Maintenance treatment of preterm labor with the oxytocin antagonist atosiban

Valenzuela, G. J., Sanchez‐Ramos, L., Romero, R. J., Silver, H. M., Koltun, W. D., Millar, L. K., Hobbins, J. C., Rayburn, W. F., Shangold, G. A., Wang, J., et al. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2000.105816 · Cited by 151 · see citing works

The Basic and Clinical Pharmacology of Nonpeptide Vasopressin Receptor Antagonists

Thibonnier, M., Coles, P., Thibonnier, A., & Shoham, M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.175 · Cited by 146 · see citing works

Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-γ-aminobutyrine-vasopressin, 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-arginine-vasopressin

Zaoral, M., Kolc, J., & Šorm, F. (1967) · Collection of Czechoslovak Chemical Communications · doi:10.1135/cccc19671250 · Cited by 142 · see citing works

The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development

Ring, R. H. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053382241 · Cited by 141 · see citing works

Pharmacological Profile of YM087, A Novel Potent Nonpeptide Vasopressin V1A and V2 Receptor Antagonist, in Vitro and in Vivo

Tahara, A., Tomura, Y., Wada, K., Kusayama, T., Tsukada, J., Takanashi, M., Yatsu, T., Uchida, W., & Tanaka, A. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36784-9 · Cited by 140 · see citing works

The oxytocin receptor antagonist atosiban inhibits cell growth via a “biased agonist” mechanism

Reversi, A., Rimoldi, V., Marrocco, T., Cassoni, P., Bussolati, G., Parenti, M., & Chini, B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409945200 · Cited by 139 · see citing works

Peripherally administered non-peptide oxytocin antagonist, L368,899®, accumulates in limbic brain areas: A new pharmacological tool for the study of social motivation in non-human primates

Boccia, M. L., Goursaud, A.-P. S., Bachevalier, J., Anderson, K. D., & Pedersen, C. A. (2007) · Hormones and Behavior · doi:10.1016/j.yhbeh.2007.05.009 · Cited by 136 · see citing works

Structural Changes in the Arginine Vasopressin Molecule that Enhance Antidiuretic Activity and Specificity1

Sawyer, W. H., Acosta, M., Baláspiri, L., JUDD, J., & Manning, M. (1974) · Endocrinology · doi:10.1210/endo-94-4-1106 · Cited by 135 · see citing works

Synthetic antagonists of the myometrial response to vasopressin and oxytocin

Melin, P., Trojnar, J., Johansson, B., Vilhardt, H., & Åkerlund, M. (1986) · Journal of Endocrinology · doi:10.1677/joe.0.1110125 · Cited by 132 · see citing works

Oxytocin and electrical stimulation of the paraventricular hypothalamic nucleus produce antinociceptive effects that are reversed by an oxytocin antagonist

Miranda-Cardenas, Y., Rojas‐Piloni, G., Martı́nez-Lorenzana, G., Rodríguez-Jiménez, J., López-Hidalgo, M. A., Freund‐Mercier, M. J., & Condés‐Lara, M. (2006) · Pain · doi:10.1016/j.pain.2006.01.029 · Cited by 131 · see citing works

Aquaretic Effect of Lixivaptan, an Oral, Non-Peptide, Selective V2 Receptor Vasopressin Antagonist, in New York Heart Association Functional Class II and III Chronic Heart Failure Patients

Abraham, W. T., Shamshirsaz, A. A., McFann, K., Oren, R. M., & Schrier, R. W. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.071 · Cited by 130 · see citing works

The Human V3Pituitary Vasopressin Receptor: Ligand Binding Profile and Density-Dependent Signaling Pathways1

Thibonnier, M., Preston, J. A., Dulin, N. O., Wilkins, P. L., Berti‐Mattera, L. N., & Mattera, R. (1997) · Endocrinology · doi:10.1210/endo.138.10.5432 · Cited by 129 · see citing works

The involvement of the vasopressin system in stress-related disorders

Landgraf, R. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706776359664 · Cited by 127 · see citing works

Molecular Cloning and Characterization of Rat V1B Vasopressin Receptor: Evidence for Its Expression in Extrapituitary Tissues

Saito, M., Sugimoto, T., Tahara, A., & Kawashima, H. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2033 · Cited by 124 · see citing works

Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges

Chini, B., & Manning, M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350737 · Cited by 123 · see citing works

Structural Requirements for Activation of Vasopressin-sensitive Adenylate Cyclase, Hormone Binding, and Antidiuretic Actions: Effects of Highly Potent Analogues and Competitive Inhibitors

Butlen, D., Guillon, G., Rajerison, R. M., Jard, S., Sawyer, W. H., & Manning, M. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13565-7 · Cited by 122 · see citing works

Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus

Robben, J. H., Sze, M., Knoers, N. V. A. M., & Deen, P. M. T. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00247.2006 · Cited by 119 · see citing works

Prenatal stress: opposite effects on anxiety and hypothalamic expression of vasopressin and corticotropin‐releasing hormone in rats selectively bred for high and low anxiety

Bosch, O. J., Krömer, S. A., & Neumann, I. D. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04576.x · Cited by 115 · see citing works

Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor.

Hirsch, A. T., Dzau, V. J., Majzoub, J. A., & Creager, M. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114182 · Cited by 115 · see citing works

Vasopressin Analogs That Antagonize Antidiuretic Responses by Rats to the Antidiuretic Hormone

Sawyer, W. H., Pang, P. K. T., SETO, J., McEnroe, M., Lammek, B., & Manning, M. (1981) · Science · doi:10.1126/science.7209515 · Cited by 115 · see citing works

Therapeutic Potential of Vasopressin Receptor Antagonists

Ali, F., Guglin, M. E., Vaitkevicius, P. V., & Ghali, J. K. (2007) · Drugs · doi:10.2165/00003495-200767060-00002 · Cited by 114 · see citing works

DESIGN AND SYNTHESIS OF POTENTIN VIVOANTAGONISTS OF OXYTOCIN

Bańkowski, K., Manning, M., Seto, J., Haldar, J., & Sawyer, W. H. (1980) · International journal of peptide & protein research · doi:10.1111/j.1399-3011.1980.tb02962.x · Cited by 112 · see citing works

Diabetes insipidus: diagnosis and treatment of a complex disease.

Makaryus, A. N., & McFarlane, S. I. (2006) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.73.1.65 · Cited by 112 · see citing works

Chapter 15 Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands

Gal, C. S., Wagnon, J., Valette, G., Garcia, G., Pascal, M., Maffrand, J., & Fur, G. L. (2002) · Progress in brain research · doi:10.1016/s0079-6123(02)39017-4 · Cited by 111 · see citing works

Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior

Ferris, C. F., Lu, S., Messenger, T. L., Guillon, C. D., Heindel, N. D., Miller, M., KOPPEL, G. A., Bruns, F., & Simon, N. G. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.01.001 · Cited by 111 · see citing works

An Overview of SSR149415, a Selective Nonpeptide Vasopressin V1b Receptor Antagonist for the Treatment of Stress-Related Disorders

Gal, C. S., Wagnon, J., Tonnerre, B., Roux, R., Garcia, G., Griebel, G., & Aulombard, A. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00035.x · Cited by 110 · see citing works

Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin

Manning, M., Kruszynski, M., Bańkowski, K., Olma, A., Lammek, B., Cheng, L., Kliś, W. A., Seto, J., Haldar, J., & Sawyer, W. H. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00122a016 · Cited by 106 · see citing works

Synthesis of Oxytocin Analogues with Replacement of Sulfur by Carbon Gives Potent Antagonists with Increased Stability

Stymiest, J. L., Mitchell, B. F., Wong, S., & Vederas, J. C. (2005) · The Journal of Organic Chemistry · doi:10.1021/jo050539l · Cited by 105 · see citing works

Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach

Oshikawa, S., Tanoue, A., Koshimizu, T.-A., Kitagawa, Y., & Tsujimoto, G. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.623 · Cited by 105 · see citing works

Design and synthesis of highly selectivein vitroandin vivouterine receptor antagonists of oxytocin: comparisons with Atosiban

Manning, M., Miteva, K., Pancheva, S. N., STOEV, S., Wo, N. C., & Chan, W. Y. (1995) · International journal of peptide & protein research · doi:10.1111/j.1399-3011.1995.tb00596.x · Cited by 99 · see citing works

Synthesis and some pharmacological properties of [4-threonine,7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid),4-threonine,7-glycine]oxytocin (hydroxy[thr4, gly7]oxytocin), and [7-glycine]oxytocin, peptides with high oxytocic-antidiuretic selectivity

Lowbridge, J., Manning, M., Haldar, J., & Sawyer, W. H. (1977) · Journal of Medicinal Chemistry · doi:10.1021/jm00211a025 · Cited by 98 · see citing works

Oxytocin agonists for preventing postpartum haemorrhage

Su, L.-L., Chong, Y. S., & Samuel, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005457.pub2 · Cited by 96 · see citing works

Characterization of a Novel, Linear Radioiodinated Vasopressin Antagonist: An Excellent Radioligand for Vasopressin V 1a Receptors

Barberis, C., Balestre, M., Jard, S., Tribollet, E., Arsenijévic, Y., Dreifuss, J. J., Bańkowski, K., Manning, M., Chan, W. Y., Schlosser, S. S., et al. (2008) · Neuroendocrinology · doi:10.1159/000126998 · Cited by 95 · see citing works

Paraventricular hypothalamic influences on spinal nociceptive processing

Condés‐Lara, M., Rojas‐Piloni, G., Martı́nez-Lorenzana, G., Rodríguez-Jiménez, J., López-Hidalgo, M. A., & Freund‐Mercier, M. J. (2006) · Brain Research · doi:10.1016/j.brainres.2006.01.050 · Cited by 94 · see citing works

Carboxy terminus of vasopressin required for activity but not binding

Manning, M., Olma, A., Kliś, W. A., Kolodziejczyk, A. M., Nawrocka, E., Misicka, A., Seto, J., & Sawyer, W. H. (1984) · Nature · doi:10.1038/308652a0 · Cited by 91 · see citing works

Gonadal Steroid Modulation of Stress-Induced Hypothalamo-Pituitary-Adrenal Activity and Anxiety Behavior: Role of Central Oxytocin

Windle, R. J., Gamble, L. E., Kershaw, Y. M., Wood, S. A., Lightman, S. L., & Ingram, C. D. (2006) · Endocrinology · doi:10.1210/en.2005-1079 · Cited by 90 · see citing works

Design, Synthesis and Some uses of Receptor-Specific Agonists and Antagonists of Vasopressin and Oxytocin

Manning, M., & Sawyer, W. H. (1993) · Journal of Receptor Research · doi:10.3109/10799899309073655 · Cited by 90 · see citing works

The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities

Morin, D., de la Cotte, N., Balestre, M., Mouillac, B., Manning, M., Breton, C., & Barberis, C. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01585-3 · Cited by 89 · see citing works

Tocolytic treatment for the management of preterm labour: a systematic review.

Tan, T. C., Devendra, K. P., Tan, L., & Tan, H. K. (2006) · PubMed · Cited by 88 · see citing works

A radioiodinated linear vasopressin antagonist: A ligand with high affinity and specificity for V1a receptors

Schmidt, A., Audigier, S., Barberis, C., Jard, S., Manning, M., Kołodziejczyk, A. S., & Sawyer, W. H. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80448-c · Cited by 83 · see citing works

1-desamino-8-d-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor

Saito, M., Tahara, A., & Sugimoto, T. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00070-1 · Cited by 82 · see citing works

Oxytocin Maintains as Well as Initiates Female Sexual Behavior: Effects of a Highly Selective Oxytocin Antagonist

Pedersen, C. A., & Boccia, M. L. (2002) · Hormones and Behavior · doi:10.1006/hbeh.2001.1736 · Cited by 81 · see citing works

Vasopressin-induced pulmonary vasodilation in rats

Walker, B. R., Haynes, J., Wang, H. L., & Voelkel, N. F. (1989) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1989.257.2.h415 · Cited by 80 · see citing works

Vasopressin V2 Receptor Binding Is Down-Regulated during Renal Escape from Vasopressin-Induced Antidiuresis

Tian, Y., Sandberg, K. L., Murase, T., Baker, E. A., Speth, R. C., & Verbalis, J. G. (2000) · Endocrinology · doi:10.1210/endo.141.1.7256 · Cited by 80 · see citing works

Orally active, nonpeptide oxytocin antagonists

Evans, B., Leighton, J. L., Rittle, K. E., Gilbert, K. F., Lundell, G. F., Gould, N. P., Hobbs, D. W., DiPardo, R. M., Veber, D. F., Pettibone, D. J., et al. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00099a020 · Cited by 79 · see citing works

Basic Pharmacological Properties of Synthetic Analogues and Homologues of the Neurohypophysial Hormones

Berde, B., & Boissonnas, R. A. (1968) · Springer eBooks · doi:10.1007/978-3-642-46127-9_16 · Cited by 77 · see citing works

Selective Agonists and Antagonists of Vasopressin

Manning, M., Bańkowski, K., & Sawyer, W. H. (1987) · Springer eBooks · doi:10.1007/978-1-4615-8129-1_8 · Cited by 77 · see citing works

Internalization and Desensitization of the Oxytocin Receptor Is Inhibited by Dynamin and Clathrin Mutants in Human Embryonic Kidney 293 Cells

Smith, M. P., Ayad, V. J., Mundell, S. J., McArdle, C. A., Kelly, E., & Bernal, A. L. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0031 · Cited by 76 · see citing works

[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors

Derick, S., Cheng, L. L., Voirol, M. J., Stoev, S., Giacomini, M., Wo, N. C., Szeto, H. H., Ben Mimoun, M., Andres, M., Gaillard, R. C., et al. (2002) · Endocrinology · doi:10.1210/en.2002-220363 · Cited by 76 · see citing works

Oxytocin Induces Proliferation and Migration in Immortalized Human Dermal Microvascular Endothelial Cells and Human Breast Tumor-Derived Endothelial Cells

Cassoni, P., Marrocco, T., Bussolati, B., Allìa, E., Munaron, L., Sapino, A., & Bussolati, G. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0024 · Cited by 76 · see citing works

Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin

Manning, M., Olma, A., Kliś, W. A., Kolodziejczyk, A. M., Seto, J., & Sawyer, W. H. (1982) · Journal of Medicinal Chemistry · doi:10.1021/jm00343a009 · Cited by 75 · see citing works

Azetidinones as vasopressin V1a antagonists

Guillon, C. D., KOPPEL, G. A., Brownstein, M., Chaney, M. O., Ferris, C. F., Lu, S., Fabio, K. M., Miller, M. J., Heindel, N. D., Hunden, D. C., et al. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.12.031 · Cited by 74 · see citing works

Arginine vasopressin stimulation of cerebral microvascular endothelial cell Na-K-Cl cotransporter activity is V1 receptor and [Ca] dependent

O’Donnell, M. E., Duong, V., Suvatne, J., Foroutan, S., & Johnson, D. M. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00001.2005 · Cited by 73 · see citing works

Identification of Residues Responsible for the Selective Binding of Peptide Antagonists and Agonists in the V2 Vasopressin Receptor

de la Cotte, N., Balestre, M., Phalipou, S., Hibert, M., Manning, M., Barberis, C., & Mouillac, B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29462 · Cited by 72 · see citing works

Pharmacokinetics, pharmacodynamics, long‐term efficacy and safety of oral 1‐deamino‐8‐d‐arginine vasopressin in adult patients with central diabetes insipidus

Lam, K. S. L., Wat, M. S., CHOI, K. L., Ip, T., Pang, R. W. C., & Kumana, C. R. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.39914.x · Cited by 72 · see citing works

Molecular pharmacology of AVP and OT receptors and therapeutic potential

Barberis, C., Morin, D., Durroux, T., Mouillac, B., Guillon, G., Seyer, R., Hibert, M., Tribollet, E., & Manning, M. (1999) · Drug News & Perspectives · doi:10.1358/dnp.1999.12.5.863621 · Cited by 71 · see citing works

Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension

Bernadich, C., Bandi, J. C., Melin, P., & Bosch, J. (1998) · Hepatology · doi:10.1002/hep.510270206 · Cited by 71 · see citing works

GABA-mediated oxytocinergic inhibition in dorsal horn neurons by hypothalamic paraventricular nucleus stimulation

Rojas-Piloni, G., López-Hidalgo, M., Martínez-Lorenzana, G., Rodríguez-Jiménez, J., & Condés-Lara, M. (2007) · Brain Research · doi:10.1016/j.brainres.2006.12.045 · Cited by 67 · see citing works

Characterization of the human liver vasopressin receptor. Profound differences between human and rat vasopressin-receptor-mediated responses suggest only a minor role for vasopressin in regulating human hepatic function

Howl, J., Ismail, T., Strain, A. J., Kirk, C. J., Anderson, D., & Wheatley, M. (1991) · Biochemical Journal · doi:10.1042/bj2760189 · Cited by 67 · see citing works

Mechanisms of Cell-surface Rerouting of an Endoplasmic Reticulum-retained Mutant of the Vasopressin V1b/V3 Receptor by a Pharmacological Chaperone

Robert, J., Auzan, C., Ventura, M. A., & Clauser, É. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m510180200 · Cited by 66 · see citing works

Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an “easy guide” to receptor pharmacology

CHINI, B., MANNING, M., & GUILLON, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00438-x · Cited by 65 · see citing works

Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues

Pettibone, D. J., Kishel, M. T., Woyden, C. J., Clineschmidt, B. V., Bock, M. G., Freidinger, R. M., Veber, D. F., & Williams, P. D. (1992) · Life Sciences · doi:10.1016/0024-3205(92)90524-s · Cited by 64 · see citing works

Vasopressin Antagonists as Aquaretic Agents for the Treatment of Hyponatremia

Palm, C., Pistrosch, F., Herbrig, K., & Gross, P. A. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.05.014 · Cited by 63 · see citing works

Synthesis and some pharmacological properties of deamino[4-threonine,8-D-arginine]vasopressin and deamino[8-D-arginine]vasopressin, highly potent and specific antidiuretic peptides, and [8-D-arginine]vasopressin and deamino-arginine-vasopressin

Manning, M., Baláspiri, L., Moehring, J., Haldar, J., & Sawyer, W. H. (1976) · Journal of Medicinal Chemistry · doi:10.1021/jm00228a023 · Cited by 62 · see citing works

Non-peptide oxytocin agonists

Pitt, G. R. W., Batt, A. R., Haigh, R. M., Penson, A., Robson, P. A., Rooker, D. P., Tartar, A. L., Trim, J. E., Yea, C., & Roe, M. B. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.04.107 · Cited by 61 · see citing works

Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist

Griffante, C., Green, A., Curcuruto, O., Haslam, C. P., Dickinson, B. A., & Arban, R. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706383 · Cited by 60 · see citing works

Reduced Hypothalamic Vasopressin Secretion Underlies Attenuated Adrenocorticotropin Stress Responses in Pregnant Rats

Ma, S., Shipston, M. J., Morilak, D. A., & Russell, J. A. (2005) · Endocrinology · doi:10.1210/en.2004-1368 · Cited by 60 · see citing works

Development of Orally Active Oxytocin Antagonists: Studies on 1-(1-{4-[1-(2-Methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl}piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and Related Pyridines

Bell, I. M., Erb, J. M., Freidinger, R. M., Gallicchio, S. N., Guare, J. P., Guidotti, M. T., Halpin, R. A., Hobbs, D. W., Homnick, C. F., Kuo, M. S., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9800797 · Cited by 60 · see citing works

Solid phase synthesis of [1-deamino,4-valine]-8-D-arginine-vasopressin (DVDAVP), a highly potent and specific antidiuretic agent possessing protracted effects

Manning, M., Baláspiri, L., Acosta, M., & Sawyer, W. H. (1973) · Journal of Medicinal Chemistry · doi:10.1021/jm00267a004 · Cited by 59 · see citing works

AVP receptor antagonists as aquaretics: review and assessment of clinical data.

Verbalis, J. G. (2006) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.73.suppl_3.s24 · Cited by 58 · see citing works

Antagonists of the antidiuretic activity of vasopressin

Kinter, L. B., Huffman, W. F., & Stassen, F. L. (1988) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1988.254.2.f165 · Cited by 58 · see citing works

Pharmacokinetics of Tocolytic Agents

Tsatsaris, V., CABROL, D., & Carbonne, B. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00001 · Cited by 58 · see citing works

Clinical evaluation of inhaled insulin

Mastrandrea, L. D., & Quattrin, T. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.019 · Cited by 58 · see citing works

SSR126768A (4-Chloro-3-[(3 R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2- oxo-2,3-dihydro-1 H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, Hydrochloride): A New Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor

Gal, C. S., Valette, G., Foulon, L., Germain, G., Advenier, C., Naline, E., Bardou, M., Martinolle, J.-P., Pouzet, B., Raufaste, D., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061200 · Cited by 56 · see citing works

1-[1-[4-[(N-Acetyl-4-piperidinyl)oxy]-2- methoxybenzoyl]piperidin-4-yl]-4H-3,1- benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.

Williams, P. D., Clineschmidt, B. V., Erb, J. M., Freidinger, R. M., Guidotti, M. T., Lis, E. V., Pawluczyk, J. M., Pettibone, D. J., & Reiss, D. R. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00023a002 · Cited by 55 · see citing works

Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist

Tahara, A., Saito, M., Sugimoto, T., Tomura, Y., Wada, K., Kusayama, T., Tsukada, J., Ishii, N., Yatsu, T., Uchida, W., et al. (1997) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005139 · Cited by 53 · see citing works

Synthesis and Characterization of Fluorescent Antagonists and Agonists for Human Oxytocin and Vasopressin V1aReceptors

Terrillon, S., Cheng, L., Stoev, S. B., Mouillac, B., Barberis, C., Manning, M., & Durroux, T. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010526+ · Cited by 48 · see citing works

Vasopressin receptors. A historical survey.

Jard, S. (1998) · PubMed · Cited by 48 · see citing works

Oral desmopressin as a new treatment modality for primary nocturnal enuresis in adolescents and adults: a double-blind, randomized, multicenter study. Dutch Enuresis Study Group.

Janknegt, R. A., Zweers, H. M. M., Delaere, K. P. J., Kloet, A. G., Khoe, S. G. S., & Arendsen, H. J. (1997) · PubMed · Cited by 48 · see citing works

Small molecule ligands for oxytocin and vasopressin receptors

Freidinger, R. M., & Pettibone, D. J. (1997) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199701)17:1 · Cited by 48 · see citing works

Pyridobenzodiazepines: A novel class of orally active, vasopressin V2 receptor selective agonists

Failli, A. A., Shumsky, J. S., Steffan, R. J., Caggiano, T. J., Williams, D. K., Trybulski, E. J., Ning, X., Lock, Y., Tanikella, T., Hartmann, D., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.10.107 · Cited by 46 · see citing works

A PHARMACOLOGIC ANALYSIS ON THE SIGNIFICANCE OF THE CHEMICAL FUNCTIONAL GROUPS OF OXYTOCIN TO ITS OXYTOCIC ACTIVITY AND ON THE EFFECT OF MAGNESIUM ON THE IN VITRO AND IN VIVO OXYTOCIC ACTIVITY OF NEUROHYPOPHYSIAL HORMONES

Chan, W. Y., & Kelley, N. (1967) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)27606-6 · Cited by 45 · see citing works

Oxytocin Action at the Lactotroph Is Required for Prolactin Surges in Cervically Stimulated Ovariectomized Rats

McKee, D. T., Poletini, M. O., Bertram, R., & Freeman, M. E. (2007) · Endocrinology · doi:10.1210/en.2007-0646 · Cited by 44 · see citing works

L-368,899, a potent orally active oxytocin antagonist for potential use in preterm labor

Pettibone, D. J., Clineschmidt, B. V., Guidotti, M. T., Lis, E. V., Reiss, D. R., Woyden, C. J., Bock, M. G., Evans, B. E., Freidinger, R. M., Hobbs, D. W., et al. (1993) · Drug Development Research · doi:10.1002/ddr.430300305 · Cited by 43 · see citing works

Oxytocin actions within the supraoptic and paraventricular nuclei: differential effects on peripheral and intranuclear vasopressin release

Neumann, I. D., Torner, L., Toschi, N., & Veenema, A. H. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00763.2005 · Cited by 43 · see citing works

Mapping the Binding Site of Arginine Vasopressin to V 1a and V 1b Vasopressin Receptors

Rodrigo, J., Peña, A., Murat, B., Trueba, M., Durroux, T., Guillon, G., & Rognan, D. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0202 · Cited by 43 · see citing works

No Stress Response of the Hypothalamo-Pituitary-Adrenal Axis in Parturient Rats: Lack of Involvement of Brain Oxytocin

Neumann, I. D., Bosch, O. J., Toschi, N., Torner, L., & Douglas, A. J. (2003) · Endocrinology · doi:10.1210/en.2003-0037 · Cited by 43 · see citing works

Ontogenesis and functional aspects of oxytocin and vasopressin gene expression in the thymus network

Hansenne, I., Rasier, G., Péqueux, C., Brilot, F., Renard, C., Breton, C., Greimers, R., Legros, J.-J., Geenen, V. G., & Martens, H. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.08.007 · Cited by 43 · see citing works

Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays

Chan, W. Y., Wo, N. C., Stoev, S., Cheng, L. L., & Manning, M. (2000) · Experimental Physiology · doi:10.1111/j.1469-445x.2000.tb00003.x · Cited by 41 · see citing works

Enhanced involvement of brain vasopressin V1 receptors in cardiovascular responses to stress in rats with myocardial infarction

Dobruch, J. T., Cudnoch‐Jędrzejewska, A., & Szczepanska‐Sadowska, E. K. (2005) · Stress · doi:10.1080/10253890500456287 · Cited by 40 · see citing works

Properties of [3H]l-Desamino-8-D-Arginine Vasopressin as a Radioligand for Vasopressin V2-Receptors in Rat Kidney*

MARCHINGO, A. J., Abrahams, J. M., Woodcock, E. A., Smith, A. I., Mendelsohn, F. A. O., & Johnston, C. I. (1988) · Endocrinology · doi:10.1210/endo-122-4-1328 · Cited by 40 · see citing works

Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin

Manning, M., Stoev, S. B., Kolodziejczyk, A. M., Kliś, W. A., Kruszynski, M., Misicka, A., Olma, A., Wo, N. C., & Sawyer, W. H. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00173a027 · Cited by 40 · see citing works

Design of Oxytocin Antagonists, which are more Selective than Atosiban

Manning, M., Stoev, S. B., Cheng, L., Wo, N. C., & Chan, W. Y. (2001) · Journal of Peptide Science · doi:10.1002/psc.339 · Cited by 39 · see citing works

FE 200 440: a selective oxytocin antagonist on the term-pregnant human uterus

Nilsson, L., Reinheimer, T. M., Steinwall, M., & Åkerlund, M. (2003) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2003.02540.x · Cited by 39 · see citing works

V2 Receptor-Mediated Vasodilation in Healthy Humans

Tagawa, T., Imaizumi, T., Shiramoto, M., Endo, T., Hironaga, K., & Takeshita, A. (1995) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199503000-00006 · Cited by 39 · see citing works

Presence of functional vasopressin receptors in spinal ventral horn neurons of young rats: a morphological and electrophysiological study

Liu, X., Tribollet, E., Ogier, R., Barberis, C., & Raggenbass, M. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02625.x · Cited by 38 · see citing works

Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin

Manning, M., Stoev, S. B., Bańkowski, K., Misicka, A., Lammek, B., Wo, N. C., & Sawyer, W. H. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00080a027 · Cited by 38 · see citing works

Synthèse de La Phe2‐Orn8‐vasopressine et de la Phe2‐oxytocine, deux analogues de la vasopressine doués d'une activité Pressorique sélective

Huguenin, R. L. (1964) · Helvetica Chimica Acta · doi:10.1002/hlca.19640470733 · Cited by 37 · see citing works

Barusiban, A New Highly Potent and Long-Acting Oxytocin Antagonist: Pharmacokinetic and Pharmacodynamic Comparison with Atosiban in a Cynomolgus Monkey Model of Preterm Labor

Reinheimer, T. M., Bee, W. H., Resendez, J. C., Meyer, J. K., Haluska, G. J., & Chellman, G. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2120 · Cited by 37 · see citing works

Pharmacological and Physiological Characterization of d[Leu4, Lys8]Vasopressin, the First V1b-Selective Agonist for Rat Vasopressin/Oxytocin Receptors

Peña, A., Murat, B., Trueba, M., Ventura, M. A., Bertrand, G., Cheng, L., Stoev, S. B., Szeto, H. H., Wo, N. C., Brossard, G., et al. (2007) · Endocrinology · doi:10.1210/en.2006-1633 · Cited by 37 · see citing works

A POTENT NEW SYNTHETIC ANALOG OF VASOPRESSIN WITH RELATIVE AGONIST SPECIFICITY FOR THE PITUITARY

Schwartz, J., Derdowska, I., Sobocińska, M. K., & Kupryszewski, G. (1991) · Endocrinology · doi:10.1210/endo-129-2-1107 · Cited by 36 · see citing works

The role of arginine vasopressin and its receptors in the normal and failing rat heart

Chandrashekhar, Y. (2003) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(03)00053-1 · Cited by 36 · see citing works

[1-.beta.-Mercapto-.beta.,.beta.-diethylpropionic acid]-8-lysine-vasopressin, a potent inhibitor of 8-lysine-vasopressin and of oxytocin

Dyckes, D. F., NESTOR, J. J. J., Ferger, M. F., & du Vigneaud, V. (1974) · Journal of Medicinal Chemistry · doi:10.1021/jm00248a028 · Cited by 35 · see citing works

Biological characterization of rodent and human vasopressin V_1breceptors using SSR-149415, a nonpeptide V_1breceptor ligand

Gal, C. S.-L., Raufaste, D., Derick, S., Blankenstein, J., Allen, J., Pouzet, B., Pascal, M., Wagnon, J., & Ventura, M. A. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00062.2007 · Cited by 35 · see citing works

The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations

Guillon, G., Derick, S., Peña, A., Cheng, L., Stoev, S., Seyer, R., Morgat, J. L., Barberis, C., Gal, C. S., Wagnon, J., et al. (2004) · Journal of Neuroendocrinology · doi:10.1111/j.0953-8194.2004.01163.x · Cited by 35 · see citing works

Pharmacology of (2 S,4 Z)-N-[(2 S)-2-Hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2′-methyl[1,1′-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a New Potent and Selective Nonpeptide Antagonist of the Oxytocin Receptor

Cirillo, R., Tos, E. G., Schwarz, M. K., Quattropani, A., Scheer, A., Missotten, M., Dorbais, J., Nichols, A. C., Borrelli, F., Giachetti, C., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049395 · Cited by 34 · see citing works

Pharmacological characterization of F‐180: a selective human V1a vasopressin receptor agonist of high affinity

Andrés, M., Trueba, M., & Guillon, G. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704634 · Cited by 33 · see citing works

Chimeric strategies for the rational design of bioactive analogs of small peptide hormones

Howl, J., Langel, Ü., Hawtin, S. R., Valkna, A., YARWOOD, N. J., Saar, K., & Wheatley, M. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.7.9212082 · Cited by 32 · see citing works

Spontaneous contractions of myometrium from humans, non-human primate and rodents are sensitive to selective oxytocin receptor antagonism in vitro

Wilson, R. J., Allen, M. J., Nandi, M., Giles, H., & Thornton, S. (2001) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2001.00226.x · Cited by 32 · see citing works

Design of Potent and Selective Agonists for the Human Vasopressin V1bReceptor Based on Modifications of [Deamino-Cys]arginine Vasopressin at Position 4

Cheng, L., Stoev, S. B., Manning, M., Derick, S., Peña, A., Mimoun, M. B., & Guillon, G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030611c · Cited by 32 · see citing works

Targeting the oxytocin receptor to relax the myometrium

Åkerlund, M. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.3.423 · Cited by 32 · see citing works

Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.

Chan, W. Y., Wo, N. C., Cheng, L., & Manning, M. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12959-5 · Cited by 31 · see citing works

Fluorescent Pseudo-Peptide Linear Vasopressin Antagonists: Design, Synthesis, and Applications,

Durroux, T., Peter, M., Turcatti, G., Chollet, A., Balestre, M., Barberis, C., & Seyer, R. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9804782 · Cited by 31 · see citing works

Through V2, not V1 receptor relating to endogenous opiate peptides, arginine vasopressin in periaqueductal gray regulates antinociception in the rat

Yang, J., Chen, J.-M., Liu, W., Song, C.-Y., & Lin, B.-C. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.07.004 · Cited by 31 · see citing works

Effects of arginine vasopressin and 1-desamino-8-D arginine vasopressin on forearm vasculature of healthy subjects and patients with a V2 receptor defect

van Lieburg, A. F., Knoers, N. V. A. M., Monnens, L. A. H., & Smits, P. (1995) · Journal of Hypertension · doi:10.1097/00004872-199512010-00034 · Cited by 31 · see citing works

Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban

Manning, M., Cheng, L., Stoev, S. B., Wo, N. C., Chan, W. Y., Szeto, H. H., Durroux, T., Mouillac, B., & Barberis, C. (2005) · Journal of Peptide Science · doi:10.1002/psc.667 · Cited by 31 · see citing works

Fluorescent and biotinylated linear peptides as selective bifunctional ligands for the V1a vasopressin receptor

Howl, J., Wang, X. F., Kirk, C. J., & Wheatley, M. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17811.x · Cited by 30 · see citing works

Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists

Chen, S., Jalandhara, N., & BATLLE, D. C. (2007) · Nature Reviews Nephrology · doi:10.1038/ncpneph0401 · Cited by 30 · see citing works

Novel approach to the design of synthetic radioiodinated linear V1A receptor antagonists of vasopressin

Manning, M., Bańkowski, K., Barberis, C., Jard, S., Elands, J., & Chan, W. Y. (1992) · International journal of peptide & protein research · doi:10.1111/j.1399-3011.1992.tb00300.x · Cited by 29 · see citing works

Discovery and Development of a New Class of Potent, Selective, Orally Active Oxytocin Receptor Antagonists

Quattropani, A., Dorbais, J., Covini, D., Pittet, P.-A., Colovray, V., Thomas, R. J., Coxhead, R., Halazy, S., Scheer, A., Missotten, M., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050645f · Cited by 29 · see citing works

Kappa Receptor Bivalent Ligands

Peng, X., & Neumeyer, J. L. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607779941251 · Cited by 29 · see citing works

Regulation of 5α-Reductase Isoforms by Oxytocin in the Rat Ventral Prostate

Assinder, S. J., Johnson, C., King, K., & Nicholson, H. D. (2004) · Endocrinology · doi:10.1210/en.2004-0711 · Cited by 28 · see citing works

Design and Synthesis of the First Selective Agonists for the Rat Vasopressin V 1b Receptor: Based on Modifications of Deamino-[Cys]arginine Vasopressin at Positions 4 and 8

Peña, A., Murat, B., Trueba, M., Ventura, M. A., Wo, N. C., Szeto, H. H., Cheng, L., Stoev, S. B., Guillon, G., & Manning, M. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm060928n · Cited by 27 · see citing works

Potent V2 vasopressin antagonists with structural changes at their C-terminals

Sawyer, W. H., Bańkowski, K., Misicka, A., Nawrocka, E., Kruszynski, M., Stoev, S., Kliś, W. A., Przybylski, J., & Manning, M. (1988) · Peptides · doi:10.1016/0196-9781(88)90022-8 · Cited by 27 · see citing works

Interaction of AT1 receptors and V1a receptors-mediated effects in the central cardiovascular control during the post-infarct state

Cudnoch‐Jędrzejewska, A., Dobruch, J. T., Puchalska, L., & Szczepanska‐Sadowska, E. K. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.01.010 · Cited by 26 · see citing works

Cardiovascular Effects of Felypressin

Cecanho, R., Junior, L. A. D. L., & Ranali, J. (2006) · Anesthesia Progress · doi:10.2344/0003-3006(2006)53[119:ceof]2.0.co;2 · Cited by 26 · see citing works

Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.

McCafferty, G., Pullen, M., Wu, C. W., Edwards, R., Allen, M., Woollard, P., Borthwick, A. D., Liddle, J., Hickey, D., Brooks, D. P., et al. (2007) · American Journal of Physiology. Regulatory Integrative and Comparative Physiology · doi:10.1152/ajpregu.00057.2007 · Cited by 26 · see citing works

Vaptans: A promising therapy in the management of advanced cirrhosis

Ginès, P. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.03.007 · Cited by 26 · see citing works

Hyponatremia: Current Treatment Strategies and the Role of Vasopressin Antagonists

Cawley, M. J. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h502 · Cited by 26 · see citing works

Characterization of a novel and selective V1B receptor antagonist

Craighead, M. W., Milne, R. J., Campbell-Wan, L., WATSON, L., Presland, J. P., THOMSON, F. J., Marston, H. M., & MacSweeney, C. P. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00440-8 · Cited by 25 · see citing works

Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [3H]-SR 121463

Gal, C. S., Raufaste, D., Double-Cazanave, E., Guillon, G., Garcia, C., Pascal, M., & Maffrand, J. P. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00322.x · Cited by 25 · see citing works

Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin

Manning, M., Kliś, W. A., Kruszynski, M., Przybylski, J., Olma, A., Wo, N. C., Pelton, G. H., & Sawyer, W. H. (1988) · International journal of peptide & protein research · doi:10.1111/j.1399-3011.1988.tb01376.x · Cited by 25 · see citing works

Oxytocin and Vasopressin Stimulate Anion Secretion by Human and Porcine Vas Deferens Epithelia1

Hagedorn, T. M., Carlin, R. W., & Schultz, B. D. (2007) · Biology of Reproduction · doi:10.1095/biolreprod.106.056762 · Cited by 25 · see citing works

G-protein coupled receptors bivalent ligands and drug design

Halazy, S. (1999) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.9.4.431 · Cited by 25 · see citing works

Oxytocin does not directly affect vascular tone in vessels from nonpregnant and pregnant rats

Miller, M. E., Davidge, S. T., & Mitchell, B. F. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00774.2001 · Cited by 25 · see citing works

New bradykinin antagonists having very high potency at B1 receptors

Gera, L., Stewart, J. M., Whalley, E. T., Burkard, M., & Zuzack, J. S. (1996) · Immunopharmacology · doi:10.1016/0162-3109(96)00100-2 · Cited by 24 · see citing works

Key Amino Acids Located within the Transmembrane Domains 5 and 7 Account for the Pharmacological Specificity of the Human V1b Vasopressin Receptor

Derick, S., Peña, A., Durroux, T., Wagnon, J., Gal, C. S., Hibert, M., Rognan, D., & Guillon, G. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0124 · Cited by 24 · see citing works

Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors

Ala, Y., Morin, D., Mahé, E., de la Cotte, N., Mouillac, B., Jard, S., Barberis, C., Tribollet, E., Dreifuss, J.-J., Sawyer, W. H., et al. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01021-2 · Cited by 23 · see citing works

Antidiuretic Effects of a Nonpeptide Vasopressin V2-Receptor Agonist, OPC-51803, Administered Orally to Rats

Nakamura, S., Hirano, T., Tsujimae, K., Aoyama, M., Kondo, K., Yamamura, Y., Mori, T., & Tominaga, M. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39000-7 · Cited by 23 · see citing works

Position Three in Vasopressin Antagonist Tolerates Conformationally Restricted and Aromatic Amino Acid Substitutions: A Striking Contrast with Vasopressin Agonists

Manning, M., Cheng, L., Stoev, S. B., Kliś, W. A., Nawrocka, E., Olma, A., Sawyer, W. H., Wo, N. C., & Chan, W. Y. (1997) · Journal of Peptide Science · doi:10.1002/(sici)1099-1387(199701)3:1 · Cited by 22 · see citing works

Biologic assays for oxytocin and vasopressin.

Wh, S. (1961) · PubMed · Cited by 22 · see citing works

[3H]desGly-NH29-d(CH2)5[D-Ileu2,Ileu4]AVP: An AVP V2 receptor antagonist radioligand

Trinder, D., Stephenson, J. M., Gao, X., Phillips, P. A., Risvanis, J., & Johnston, C. I. (1991) · Peptides · doi:10.1016/0196-9781(91)90194-t · Cited by 22 · see citing works

Trends in peptide drug discovery

Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 2,022 · see citing works

Oxytocin: The Great Facilitator of Life

Lee, H.-J., Macbeth, A. H., Pagani, J., & Young, W. S. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.04.001 · Cited by 1,037 · see citing works

The oxytocin receptor: from intracellular signaling to behavior

Jurek, B., & Neumann, I. D. (2018) · Physiological Reviews · doi:10.1152/physrev.00031.2017 · Cited by 999 · see citing works

Oxytocin-dependent consolation behavior in rodents

Burkett, J. P., Andari, E., Johnson, Z. V., Curry, D. C., de Waal, F. B. M., & Young, L. J. (2016) · Science · doi:10.1126/science.aac4785 · Cited by 692 · see citing works

Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02303.x · Cited by 423 · see citing works

Oxytocin is an age-specific circulating hormone that is necessary for muscle maintenance and regeneration

Elabd, C., Cousin, W., Upadhyayula, P., Chen, R. Y., Chooljian, M. S., Li, J., Kung, S., Jiang, K. P., & Conboy, I. M. (2014) · Nature Communications · doi:10.1038/ncomms5082 · Cited by 411 · see citing works

Vasopressin V1a and V1b Receptors: From Molecules to Physiological Systems

Koshimizu, T., Nakamura, K., Egashira, N., Hiroyama, M., Nonoguchi, H., & Tanoue, A. (2012) · Physiological Reviews · doi:10.1152/physrev.00035.2011 · Cited by 413 · see citing works

Is oxytocin “nature’s medicine”

Carter, C. S., Kenkel, W. M., MacLean, E. L., Wilson, S. R., Perkeybile, A. M., Yee, J. R., Ferris, C. F., Nazarloo, H. P., Porges, S. W., Davis, J. M., et al. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019398 · Cited by 394 · see citing works

Neural mechanisms of mother–infant bonding and pair bonding: Similarities, differences, and broader implications

Numan, M., & Young, L. J. (2016) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.05.015 · Cited by 355 · see citing works

Biased Oxytocinergic Modulation of Midbrain Dopamine Systems

Xiao, L., Priest, M. F., Nasenbeny, J., Lu, T., & Kozorovitskiy, Y. (2017) · Neuron · doi:10.1016/j.neuron.2017.06.003 · Cited by 292 · see citing works

REVIEW: Oxytocin: Crossing the Bridge between Basic Science and Pharmacotherapy

Viéro, C., Shibuya, I., Kitamura, N., Verkhratsky, A., Fujihara, H., Katoh, A., Ueta, Y., Zingg, H. H., Chvátal, A., Syková, E., et al. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00185.x · Cited by 250 · see citing works

Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery

Song, Z., & Albers, H. E. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.10.004 · Cited by 244 · see citing works

Species, sex and individual differences in the vasotocin/vasopressin system: relationship to neurochemical signaling in the social behavior neural network

Albers, H. E. (2015) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.07.001 · Cited by 200 · see citing works

Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy

Rahmeh, R., Damian, M., Cottet, M., Orcel, H., Mendre, C., Durroux, T., Sharma, K. S., Durand, G., Pucci, B., Trinquet, E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201093109 · Cited by 196 · see citing works

Functional Selective Oxytocin-derived Agonists Discriminate between Individual G Protein Family Subtypes

Busnelli, M., Saulière, A., Manning, M., Bouvier, M., Galès, C., & Chini, B. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277178 · Cited by 195 · see citing works

Histone deacetylase inhibitors facilitate partner preference formation in female prairie voles

Wang, H., Duclot, F., Liu, Y., Wang, Z., & Kabbaj, M. (2013) · Nature Neuroscience · doi:10.1038/nn.3420 · Cited by 173 · see citing works

Sex-specific modulation of juvenile social play by vasopressin

Veenema, A. H., Bredewold, R., & De Vries, G. J. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.06.002 · Cited by 166 · see citing works

The Oxytocin–Vasopressin Pathway in the Context of Love and Fear

Carter, C. S. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00356 · Cited by 162 · see citing works

Isotocin regulates paternal care in a monogamous cichlid fish

O’Connell, L. A., Matthews, B. J., & Hofmann, H. A. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2012.03.009 · Cited by 156 · see citing works

RNAi knockdown of oxytocin receptor in the nucleus accumbens inhibits social attachment and parental care in monogamous female prairie voles

Keebaugh, A. C., Barrett, C. E., Laprairie, J. L., Jenkins, J. J., & Young, L. J. (2015) · Social Neuroscience · doi:10.1080/17470919.2015.1040893 · Cited by 150 · see citing works

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors

Juul, K. V., Bichet, D. G., Nielsen, S., & Nørgaard, J. P. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00604.2013 · Cited by 156 · see citing works

Sex-specific modulation of juvenile social play behavior by vasopressin and oxytocin depends on social context

Bredewold, R., Smith, C. J. W., Dumais, K. M., & Veenema, A. H. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00216 · Cited by 157 · see citing works

Generation of neuropeptidergic hypothalamic neurons from human pluripotent stem cells

Merkle, F. T., Maroof, A. M., Wataya, T., Sasai, Y., Studer, L., Eggan, K. C., & Schier, A. F. (2015) · Development · doi:10.1242/dev.117978 · Cited by 152 · see citing works

Adolescent oxytocin exposure causes persistent reductions in anxiety and alcohol consumption and enhances sociability in rats

Bowen, M. T., Carson, D. S., Spiro, A., Arnold, J. C., & McGregor, I. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027237 · Cited by 143 · see citing works

Social functions of individual vasopressin–oxytocin cell groups in vertebrates: What do we really know?

Kelly, A. M., & Goodson, J. L. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.04.005 · Cited by 141 · see citing works

Sex differences in the regulation of social and anxiety-related behaviors: insights from vasopressin and oxytocin brain systems

Bredewold, R., & Veenema, A. H. (2018) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2018.02.011 · Cited by 144 · see citing works

Oxytocin receptor knockout mice display deficits in the expression of autism-related behaviors

Pobbe, R. L. H., Pearson, B. L., Defensor, E. B., Bolivar, V. J., Young, W. S., Lee, H., Blanchard, D. C., & Blanchard, R. J. (2011) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.10.010 · Cited by 139 · see citing works

Modulating Oxytocin Activity and Plasma Stability by Disulfide Bond Engineering

Muttenthaler, M., Andersson, Å., de Araujo, A. D., Dekan, Z., Lewis, R. J., & Alewood, P. F. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100989w · Cited by 138 · see citing works

Oxytocin, vasopressin, and the motivational forces that drive social behaviors

Caldwell, H. K., & Albers, H. E. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_390 · Cited by 129 · see citing works

Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor

Ramos, L., Hicks, C., Kevin, R., Caminer, A., Narlawar, R., Kassiou, M., & McGregor, I. S. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.125 · Cited by 128 · see citing works

Oxytocin Regulates Stress-InducedCrfGene Transcription through CREB-Regulated Transcription Coactivator 3

Jurek, B., Slattery, D. A., Hiraoka, Y., Liu, Y., Nishimori, K., Aguilera, G., Neumann, I. D., & van den Burg, E. H. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1345-14.2015 · Cited by 124 · see citing works

The Oxytocin-Oxytocin Receptor System and Its Antagonists as Tocolytic Agents

Vrachnis, N., Malamas, F. M., Sifakis, S., Deligeoroglou, E., & Iliodromiti, Z. (2011) · International Journal of Endocrinology · doi:10.1155/2011/350546 · Cited by 122 · see citing works

The neurobiological causes and effects of alloparenting

Kenkel, W. M., Perkeybile, A. M., & Carter, C. S. (2016) · Developmental Neurobiology · doi:10.1002/dneu.22465 · Cited by 120 · see citing works

The orgasmic history of oxytocin: Love, lust, and labor

Magon, N., & Kalra, S. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.84851 · Cited by 127 · see citing works

A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus

Li, J. H., Chou, C., Li, B., Gavrilova, O., Eisner, C. B., Schnermann, J. B., Anderson, S. A., Deng, C., Knepper, M. A., & Wess, J. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39680 · Cited by 116 · see citing works

Neurohypophyseal hormones manipulation modulate social and anxiety-related behavior in zebrafish

Braida, D., Donzelli, A., Martucci, R., Capurro, V., Busnelli, M., Chini, B., & Sala, M. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2482-2 · Cited by 116 · see citing works

The vasopressin Avpr1b receptor: Molecular and pharmacological studies

Roper, J. A., O'Carroll, A.-M., Young, W. S., & Lolait, S. (2010) · Stress · doi:10.3109/10253890.2010.512376 · Cited by 116 · see citing works

Distribution of vasopressin and oxytocin binding sites in the brain and upper spinal cord of the common marmoset

Schorscher-Petcu, A., Dupré, A., & Tribollet, E. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.06.016 · Cited by 111 · see citing works

Physiology of invertebrate oxytocin and vasopressin neuropeptides

Gruber, C. W. (2014) · Experimental Physiology · doi:10.1113/expphysiol.2013.072561 · Cited by 110 · see citing works

Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors

Busnelli, M., Bulgheroni, E., Manning, M., Kleinau, G., & Chini, B. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.202994 · Cited by 102 · see citing works

Central administration of oxytocin receptor ligands affects cued fear extinction in rats and mice in a timepoint-dependent manner

Toth, I., Neumann, I. D., & Slattery, D. A. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2702-4 · Cited by 107 · see citing works

Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors

Gruber, C. W., Muttenthaler, M., & Freissmuth, M. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793292474 · Cited by 107 · see citing works

A brief history of oxytocin and its role in modulating psychostimulant effects

Carson, D. S., Guastella, A. J., Taylor, E. R., & McGregor, I. S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112473788 · Cited by 105 · see citing works

Elucidating Solution Structures of Cyclic Peptides Using Molecular Dynamics Simulations

Damjanovic, J., Miao, J., Huang, H., & Lin, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01087 · Cited by 104 · see citing works

Variation in vasopressin receptor (Avpr1a) expression creates diversity in behaviors related to monogamy in prairie voles

Barrett, C. E., Keebaugh, A. C., Ahern, T. H., Bass, C. E., Terwilliger, E. F., & Young, L. J. (2013) · Hormones and Behavior · doi:10.1016/j.yhbeh.2013.01.005 · Cited by 100 · see citing works

Treatment of Neurohypophyseal Diabetes Insipidus

Oiso, Y., Robertson, G. L., Nørgaard, J. P., & Juul, K. V. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2326 · Cited by 101 · see citing works

A Review of Oxytocin and Arginine-Vasopressin Receptors and Their Modulation of Autism Spectrum Disorder

Cataldo, I., Azhari, A., & Esposito, G. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00027 · Cited by 95 · see citing works

Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date

Lee, M. R., Rohn, M. C. H., Tanda, G., & Leggio, L. (2016) · CNS Drugs · doi:10.1007/s40263-016-0313-z · Cited by 97 · see citing works

An Essential Role of the Arginine Vasotocin System in Mate-Guarding Behaviors in Triadic Relationships of Medaka Fish (Oryzias latipes)

Yokoi, S., Okuyama, T., Kamei, Y., Naruse, K., Taniguchi, Y., Ansai, S., Kinoshita, M., Young, L. J., Takemori, N., Kubo, T., et al. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005009 · Cited by 95 · see citing works

Beyond the hype and hope: critical considerations for intranasal oxytocin research in autism spectrum disorder

Alvares, G. A., Quintana, D. S., & Whitehouse, A. J. O. (2017) · Autism Research · doi:10.1002/aur.1692 · Cited by 91 · see citing works

Social interaction prevents the development of depressive-like behavior post nerve injury in mice: a potential role for oxytocin

Norman, G. J., Karelina, K., Morris, J. S., Zhang, N., Cochran, M., & Courtney DeVries, A. (2010) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181de8678 · Cited by 88 · see citing works

Arginine‐vasopressin and the regulation of aggression in female Syrian hamsters (<i>Mesocricetus auratus</i>)

Gutzler, S. J., Karom, M., Erwin, W. D., & Albers, H. E. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07190.x · Cited by 86 · see citing works

Oxytocin receptor dynamics in the brain across development and species

Vaidyanathan, R., & Hammock, E. A. D. (2016) · Developmental Neurobiology · doi:10.1002/dneu.22403 · Cited by 82 · see citing works

Oxytocin in the medial prefrontal cortex attenuates anxiety: Anatomical and receptor specificity and mechanism of action

Sabihi, S., Dong, S. M., Maurer, S., Goodpaster, C. M., & Leuner, B. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.024 · Cited by 84 · see citing works

Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species

Muttenthaler, M., Andersson, Å., Vetter, I., Menon, R., Busnelli, M., Ragnarsson, L. K. N., Bergmayr, C., Arrowsmith, S., Deuis, J. R., Chiu, H. S., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aan3398 · Cited by 79 · see citing works

The nonpeptide oxytocin receptor agonist WAY 267,464: receptor-binding profile, prosocial effects and distribution of c-Fos expression in adolescent rats

Hicks, C., Jorgensen, W., Brown, C., Fardell, J., Koehbach, J., Gruber, C. W., Kassiou, M., Hunt, G. E., & McGregor, I. S. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02311.x · Cited by 73 · see citing works

Oxytocin receptor knockout prairie voles generated by CRISPR/Cas9 editing show reduced preference for social novelty and exaggerated repetitive behaviors

Horie, K., Inoue, K., Suzuki, S., Adachi, S., Yada, S., Hirayama, T., Hidema, S., Young, L. J., & Nishimori, K. (2019) · Hormones and Behavior · doi:10.1016/j.yhbeh.2018.10.011 · Cited by 77 · see citing works

Social Novelty Investigation in the Juvenile Rat: Modulation by the μ‐Opioid System

Smith, C. J. W., Wilkins, K. B., Mogavero, J. N., & Veenema, A. H. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12301 · Cited by 72 · see citing works

Oxytocin in the nucleus accumbens core reduces reinstatement of methamphetamine‐seeking behaviour in rats

Baracz, S. J., Everett, N. A., McGregor, I. S., & Cornish, J. L. (2014) · Addiction Biology · doi:10.1111/adb.12198 · Cited by 74 · see citing works

Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding

Svensson, P. J., Bergqvist, P. B. F., Juul, K. V., & Berntorp, E. E. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.03.001 · Cited by 74 · see citing works

Central vasopressin V1a receptor activation is independently necessary for both partner preference formation and expression in socially monogamous male prairie voles

Donaldson, Z. R., Spiegel, L., & Young, L. J. (2010) · Behavioral Neuroscience · doi:10.1037/a0018094 · Cited by 71 · see citing works

Involvement of the oxytocin system in the bed nucleus of the stria terminalis in the sex-specific regulation of social recognition

Dumais, K. M., Alonso, A. G., Immormino, M. A., Bredewold, R., & Veenema, A. H. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.11.007 · Cited by 72 · see citing works

A review of recent progress (2002-2012) on the biological activities of pyrazoles

Pérez‐Fernández, R., Goya, P., & Elguero, J. (2013) · ARKIVOC · doi:10.3998/ark.5550190.p008.131 · Cited by 71 · see citing works

The role of oxytocin in alcohol and drug abuse

King, C. E., Gano, A., & Becker, H. C. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146761 · Cited by 66 · see citing works

Preeclampsia and the brain: neural control of cardiovascular changes during pregnancy and neurological outcomes of preeclampsia

Logue, O. C., George, E. M., & Bidwell, G. L. (2016) · Clinical Science · doi:10.1042/cs20160108 · Cited by 66 · see citing works

Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain

Goodin, B. R., Ness, T. J., & Robbins, M. T. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666141027111843 · Cited by 66 · see citing works

Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an “easy guide” to receptor pharmacology

CHINI, B., MANNING, M., & GUILLON, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00438-x · Cited by 65 · see citing works

Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides

Glavaš, M., Gitlin‐Domagalska, A., Dębowski, D., Ptaszyńska, N., Łęgowska, A., & Rolka, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063068 · Cited by 62 · see citing works

Translational aspect in peptide drug discovery and development: An emerging therapeutic candidate

Anand, U., Bandyopadhyay, A., Jha, N. K., de la Lastra, J. M. P., & Dey, A. (2022) · BioFactors · doi:10.1002/biof.1913 · Cited by 62 · see citing works

Navigating Monogamy: Nonapeptide Sensitivity in a Memory Neural Circuit May Shape Social Behavior and Mating Decisions

Ophir, A. G. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00397 · Cited by 62 · see citing works

Insights into the molecular evolution of oxytocin receptor ligand binding

Koehbach, J., Stockner, T., Bergmayr, C., Muttenthaler, M., & Gruber, C. W. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120256 · Cited by 61 · see citing works

Arginine Vasotocin Regulation of Interspecific Cooperative Behaviour in a Cleaner Fish

Soares, M. C., Bshary, R., Mendonça, R., Grutter, A. S., & Oliveira, R. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039583 · Cited by 60 · see citing works

Comparing vasopressin and oxytocin fiber and receptor density patterns in the social behavior neural network: implications for cross-system signaling

Smith, C. J. W., DiBenedictis, B. T., & Veenema, A. H. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.02.001 · Cited by 59 · see citing works

The oxytocin receptor signalling system and breast cancer: a critical review

Liu, H., Gruber, C. W., Alewood, P. F., Möller, A., & Muttenthaler, M. (2020) · Oncogene · doi:10.1038/s41388-020-01415-8 · Cited by 58 · see citing works

More than just mothers: The neurobiological and neuroendocrine underpinnings of allomaternal caregiving

Glasper, E. R., Kenkel, W. M., Bick, J. R., & Rilling, J. K. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.02.005 · Cited by 54 · see citing works

A constructive replication of the association between the oxytocin receptor genotype and parenting.

Klahr, A. M., Klump, K. L., & Burt, S. A. (2014) · Journal of Family Psychology · doi:10.1037/fam0000034 · Cited by 53 · see citing works

Control of neurohypophysial hormone secretion, blood osmolality and volume in pregnancy.

Brunton, P. J., Velmurugan, S., & Ja, R. (2008) · PubMed · Cited by 52 · see citing works

Anxiolytic effects of oxytocin in cue-induced cocaine seeking behavior in rats

Morales-Rivera, A., Hernández-Burgos, M. M., Martínez-Rivera, A., Pérez-Colón, J., Rivera, R., Montalvo, J., Rodríguez-Borrero, E., & Maldonado-Vlaar, C. S. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3553-y · Cited by 50 · see citing works

Global map of oxytocin/vasopressin-like neuropeptide signalling in insects

Liutkevičiūtė, Z., Koehbach, J., Eder, T., Gil‐Mansilla, E., & Gruber, C. W. (2016) · Scientific Reports · doi:10.1038/srep39177 · Cited by 50 · see citing works

Exploring bioactive peptides from natural sources for oxytocin and vasopressin drug discovery

Gruber, C. W., Koehbach, J., & Muttenthaler, M. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.108 · Cited by 49 · see citing works

The Contribution of Oxytocin and Vasopressin to Mammalian Social Behavior: Potential Role in Autism Spectrum Disorder

Harony, H., & Wagner, S. (2010) · Neurosignals · doi:10.1159/000321035 · Cited by 62 · see citing works

Vasopressin and oxytocin excite MCH neurons, but not other lateral hypothalamic GABA neurons

Yao, Y., Fu, L., Zhang, X., & van den Pol, A. N. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00452.2011 · Cited by 48 · see citing works

Oxytocin Promotes Accurate Fear Discrimination and Adaptive Defensive Behaviors

Olivera-Pasilio, V., & Dabrowska, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.583878 · Cited by 46 · see citing works

Oxytocin, Erectile Function and Sexual Behavior: Last Discoveries and Possible Advances

Melis, M. R., & Argiolas, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910376 · Cited by 44 · see citing works

Development of a human vasopressin V1a-receptor antagonist from an evolutionary-related insect neuropeptide

Giglio, M. G. D., Muttenthaler, M., Harpsøe, K., Liutkevičiūtė, Z., Keov, P., Eder, T., Rattei, T., Arrowsmith, S., Wray, S., Marek, A., et al. (2017) · Scientific Reports · doi:10.1038/srep41002 · Cited by 44 · see citing works

Association between Genetic Variation in the Oxytocin Receptor Gene and Emotional Withdrawal, but not between Oxytocin Pathway Genes and Diagnosis in Psychotic Disorders

Haram, M., Tesli, M., Bettella, F., Djurovic, S., Andreassen, O. A., & Melle, I. S. (2015) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2015.00009 · Cited by 42 · see citing works

Involvement of the oxytocin system in the nucleus accumbens in the regulation of juvenile social novelty-seeking behavior

Smith, C. J. W., Mogavero, J. N., Tulimieri, M. T., & Veenema, A. H. (2017) · Hormones and Behavior · doi:10.1016/j.yhbeh.2017.05.005 · Cited by 42 · see citing works

Oxytocin in the Male Reproductive Tract; The Therapeutic Potential of Oxytocin-Agonists and-Antagonists

Stadler, B., Whittaker, M. R., Exintaris, B., & Middendorff, R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.565731 · Cited by 41 · see citing works

Cysteine-Rich Mini-Proteins in Human Biology

Lavergne, V., Taft, R. J., & Alewood, P. F. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612802652411 · Cited by 41 · see citing works

Role of the oxytocin system in amygdala subregions in the regulation of social interest in male and female rats

Dumais, K. M., Alonso, A. G., Bredewold, R., & Veenema, A. H. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.05.036 · Cited by 40 · see citing works

Nonapeptide influences on social behaviour: effects of vasotocin and isotocin on shoaling and interaction in zebrafish

Lindeyer, C. M., Langen, E. M. A., Swaney, W. T., & Reader, S. M. (2015) · Behaviour · doi:10.1163/1568539x-00003261 · Cited by 37 · see citing works

Neuropeptide signalling in the central nucleus of the amygdala

van den Burg, E. H., & Stoop, R. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2862-6 · Cited by 41 · see citing works

Role of Oxytocin and Vasopressin in Neuropsychiatric Disorders: Therapeutic Potential of Agonists and Antagonists

Cid-Jofré, V., Moreno, M., Reyes-Parada, M. I., & Renard, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112077 · Cited by 39 · see citing works

Segregation of calcium signalling mechanisms in magnocellular neurones and terminals

Dayanithi, G., Forostyak, O., Ueta, Y., Verkhratsky, A., & Toescu, E. C. (2012) · Cell Calcium · doi:10.1016/j.ceca.2012.02.002 · Cited by 38 · see citing works

Oxytocin modulates dopamine-mediated reward in the rat subthalamic nucleus

Baracz, S. J., & Cornish, J. L. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2012.12.003 · Cited by 38 · see citing works

Vasopressin stimulates the proliferation and differentiation of red blood cell precursors and improves recovery from anemia

Mayer, B., Németh, K., Krepuska, M., Myneni, V. D., Maric, D., Tisdale, J. F., Hsieh, M. M., Uchida, N., Lee, H., Nemeth, M. J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aao1632 · Cited by 38 · see citing works

The Involvement of Oxytocin in the Subthalamic Nucleus on Relapse to Methamphetamine-Seeking Behaviour

Baracz, S. J., Everett, N. A., & Cornish, J. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136132 · Cited by 37 · see citing works

Excitation of Tuberoinfundibular Dopamine Neurons by Oxytocin: Crosstalk in the Control of Lactation

Briffaud, V., Williams, P., Courty, J., & Broberger, C. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.2633-14.2015 · Cited by 37 · see citing works

Vasopressin Protects Hippocampal Neurones in Culture Against Nutrient Deprivation or Glutamate‐Induced Apoptosis

Chen, J., & Aguilera, G. (2010) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2010.02054.x · Cited by 37 · see citing works

Oxytocin and enhancement of the positive valence of social affiliation memories: An autobiographical memory study

Cardoso, C., Orlando, M. A., Brown, C. A., & Ellenbogen, M. A. (2014) · Social Neuroscience · doi:10.1080/17470919.2013.873079 · Cited by 37 · see citing works

Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02303.x · Cited by 423 · see citing works

Design, Synthesis and Some uses of Receptor-Specific Agonists and Antagonists of Vasopressin and Oxytocin

Manning, M., & Sawyer, W. H. (1993) · Journal of Receptor Research · doi:10.3109/10799899309073655 · Cited by 90 · see citing works

Molecular Pharmacology of Human Vasopressin Receptors

Thibonnier, M., Conarty, D. M., Preston, J. A., Wilkins, P. L., Berti‐Mattera, L. N., & Mattera, R. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4871-3_34 · Cited by 145 · see citing works

Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists

Thibonnier, M. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.5.729 · Cited by 23 · see citing works

Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays

Chan, W. Y., Wo, N. C., Stoev, S., Cheng, L. L., & Manning, M. (2000) · Experimental Physiology · doi:10.1111/j.1469-445x.2000.tb00003.x · Cited by 41 · see citing works